A share price of Cytokinetics Inc [CYTK] is currently trading at $56.67, up 2.09%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CYTK shares have gain 4.60% over the last week, with a monthly amount glided 3.83%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on January 24, 2024, when UBS downgraded its rating to a Neutral and also boosted its price target to $92 from $61. Previously, Morgan Stanley downgraded its rating to Equal-Weight on January 05, 2024, and elevated its price target to $90. On November 09, 2023, Goldman initiated with a Buy rating and assigned a price target of $50 on the stock. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $66 on November 07, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $58 as its price target on August 15, 2023. BofA Securities started tracking with a Neutral rating for this stock on February 17, 2023, and assigned it a price target of $49. In a note dated December 23, 2022, Needham reiterated an Buy rating on this stock and revised its target price from $60 to $58.
Cytokinetics Inc experienced fluctuations in its stock price throughout the past year between $25.98 and $110.25. Currently, Wall Street analysts expect the stock to reach $82.67 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $56.67 at the most recent close of the market. An investor can expect a potential return of 45.88% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Trailing Twelve Months sales for Cytokinetics Inc [NASDAQ:CYTK] were 3.75M which represents -81.90% decline. Gross Profit Margin for this corporation currently stands at -45.48% with Operating Profit Margin at -132.72%, Pretax Profit Margin comes in at -141.42%, and Net Profit Margin reading is -141.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is 1.37 and Total Capital is -0.69. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.61.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.44 points at the first support level, and at 54.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 57.31, and for the 2nd resistance point, it is at 57.95.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cytokinetics Inc [NASDAQ:CYTK] is 7.19. Further, the Quick Ratio stands at 7.19, while the Cash Ratio is 1.35. Considering the valuation of this stock, the price to sales ratio is 1732.74.
Transactions by insiders
Recent insider trading involved Harrington Robert Arthur, Director, that happened on Jul 05 ’24 when 253.0 shares were sold. President & CEO, Blum Robert I completed a deal on Jul 01 ’24 to sell 11500.0 shares. Meanwhile, Director PARSHALL B LYNNE sold 5000.0 shares on Jul 01 ’24.
